Get notified when NRIX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsNurix Therapeutics swung to a net income of $549.8M in the fiscal third quarter, driven by $653.2M of license revenue from the new Roche collaboration.
Filed October 13, 2026 · Period ending August 31, 2026 · Compared to 10-Q Oct 9, 2025 · ~1 min read
Key Changes
-
high
Total revenue surged to $673.1M from $7.9M, with license revenue of $653.2M recognized under the Roche Collaboration Agreement.
-
high
Cash, cash equivalents and marketable securities totaled $1.1 billion as of August 31, 2026, which management believes is sufficient to fund operations for at least the next 12 months.
-
medium
Nurix discontinued clinical development of zelebrudomide (NX-2127) in August 2026 as part of a strategic prioritization of its wholly owned oncology portfolio.
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (TLRY 10-Q) is open in full — no account needed.
Partner
Trade NRIX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Oct 13, 2026 · How we verify